CureVac says COVID vaccine produced immune response in early-stage trial

CureVac says COVID vaccine produced immune response in early-stage trial Germany's CureVac AG said on Friday its second-generation COVID-19 vaccine produced virus-neutralizing antibodies against the BA.1 subvariant of Omicron, based on preliminary data from an early-stage trial. Reuters Reuters

...

The company said the vaccine was shown to be generally well tolerated in the trial. Younger adults showed the presence of neutralizing antibodies beginning at the lowest tested dose, data showed.

...